Fibromyalgia Drug Patent Application Filed by Premier Biomedical

Fibromyalgia Drug Patent Application Filed by Premier Biomedical

El Paso, Texas-based Premier Biomedical Inc. announced it has filed a provisional patent application on a second drug, in addition to Feldetrex, for the treatment of fibromyalgia (FM), alcohol and chemical addiction, multiple sclerosis (MS) symptoms and neuropathic pain.

Established in 2010, Premier Biomedical is a biotechnology research company dedicated to the discovery, development, and commercialization of medical treatments for a broad spectrum of diseases – including novel therapies for muscular dystrophy, atherosclerosis, neurofibromatosis and breast cancer. Premier Biomedical has made license agreements to obtain the technology behind numerous provisional patents in the U.S. and a PCT Europe National Patent, and has set partnerships with the Department of Defense Center of Expertise at the William Beaumont Army Medical Center.

Premier’s Feldetrex’s submission to the U.S. Food and Drug Administration (FDA) for the treatment of fibromyalgia was announced in 2015. Feldetrex is a drug combination intended to treat the symptoms affecting fibromyalgia patients, including anxiety and fatigue, sleeping disturbances, morning stiffness, painful tender points and chronic muscle pain.

In last year’s announcement, Premier’s chairman of the Scientific Advisory Board, Mitchell S. Felder, M.D., said, “We are very excited about this drug’s ability to relieve the symptoms of fibromyalgia without many of the negative side effects associated with many of the current drug treatments.”

With no additional details, a recent press release adds that the new patent application for the second drug will also compete in this area of healthcare — a $16 billion annual market.

In the press release, Premier Biomedical President and CEO William A. Hartman said, “We are continuing to advance our technology to improve and expand our healthcare products to help relieve the pain and suffering of patients afflicted with these diseases and conditions, not only here in the U.S., but also in Brazil, Asia and Europe through pending and future joint ventures.”

Leave a Comment

Your email address will not be published. Required fields are marked *